Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 1 March 2024, including: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Optimistic IPO Outlook For Biopharma Fueled By Early Trends" - Scrip, 28 Feb, 2024.)
(Also see "Best-In-Class In MASH? Boehringer’s Hopes Raised By Glucagon/GLP-1 Phase II Results" - Scrip, 26 Feb, 2024.)
(Also see "Viking Emerges As Obesity Contender With Strong Phase II Readout" - Scrip, 27 Feb, 2024.)
(Also see "Incyte Enters A Data-Rich Year On Path To Portfolio Diversification" - Scrip, 27 Feb, 2024.)
(Also see "China HPV Demand Shaping Merck But Competitors Catching Up" - Scrip, 28 Feb, 2024.)